Daisuke Koshiyama1, Kenji Kirihara1, Mariko Tada1, Tatsuya Nagai2, Mao Fujioka1, Shinsuke Koike3, Motomu Suga4, Tsuyoshi Araki1, Kiyoto Kasai5. 1. Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 2. Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Psychiatry, Kawamuro Memorial Hospital, Niigata, Japan. 3. Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; University of Tokyo Institute for Diversity & Adaptation of Human Mind (UTIDAHM), Tokyo, Japan; Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, The University of Tokyo, Tokyo, Japan. 4. Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Rehabilitation, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 5. Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Electronic address: kasaik-tky@umin.net.
Abstract
BACKGROUND: Mismatch negativity (MMN) is a candidate biomarker for early stages of psychosis. Although an association among duration MMN (dMMN), cognitive deficits, and functional outcome in chronic schizophrenia has been shown by a large-scale study, the effects of deviant type and clinical stages have not been investigated. METHODS: We investigated the relationships among dMMN, frequency MMN (fMMN), global functioning, and cognitive function in early stages of psychosis. The participants included 26 individuals with recent-onset schizophrenia (ROSZ), 30 individuals with ultra-high risk (UHR), and 20 healthy controls. RESULTS: The correlational analyses revealed that dMMN amplitude, which was impaired in the ROSZ group compared to the healthy controls, correlated with global functioning (Global Assessment of Functioning-Functioning scale) in the ROSZ (r=-0.45) and UHR (r=-0.37) groups. The amplitude of fMMN, which did not differ among the groups, correlated with working memory (r=-0.57) only in the ROSZ group. The path analyses indicated that dMMN had a direct effect on global functioning in the ROSZ and UHR groups while fMMN had a direct effect on working memory only in the ROSZ group. CONCLUSIONS: Our findings suggested that the association between MMN and global functioning was specific to the duration deviant and was already present in early stages of psychosis. These findings confirm the usefulness of dMMN as a biological marker of early psychosis to guide treatment interventions.
BACKGROUND: Mismatch negativity (MMN) is a candidate biomarker for early stages of psychosis. Although an association among duration MMN (dMMN), cognitive deficits, and functional outcome in chronic schizophrenia has been shown by a large-scale study, the effects of deviant type and clinical stages have not been investigated. METHODS: We investigated the relationships among dMMN, frequency MMN (fMMN), global functioning, and cognitive function in early stages of psychosis. The participants included 26 individuals with recent-onset schizophrenia (ROSZ), 30 individuals with ultra-high risk (UHR), and 20 healthy controls. RESULTS: The correlational analyses revealed that dMMN amplitude, which was impaired in the ROSZ group compared to the healthy controls, correlated with global functioning (Global Assessment of Functioning-Functioning scale) in the ROSZ (r=-0.45) and UHR (r=-0.37) groups. The amplitude of fMMN, which did not differ among the groups, correlated with working memory (r=-0.57) only in the ROSZ group. The path analyses indicated that dMMN had a direct effect on global functioning in the ROSZ and UHR groups while fMMN had a direct effect on working memory only in the ROSZ group. CONCLUSIONS: Our findings suggested that the association between MMN and global functioning was specific to the duration deviant and was already present in early stages of psychosis. These findings confirm the usefulness of dMMN as a biological marker of early psychosis to guide treatment interventions.
Authors: Daisuke Koshiyama; Michael L Thomas; Makoto Miyakoshi; Yash B Joshi; Juan L Molina; Kumiko Tanaka-Koshiyama; Joyce Sprock; David L Braff; Neal R Swerdlow; Gregory A Light Journal: Schizophr Bull Date: 2021-03-16 Impact factor: 9.306
Authors: Brian J Roach; Holly K Hamilton; Peter Bachman; Aysenil Belger; Ricardo E Carrión; Erica Duncan; Jason Johannesen; Joshua G Kenney; Gregory Light; Margaret Niznikiewicz; Jean Addington; Carrie E Bearden; Emily M Owens; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry Seidman; Ming Tsuang; Elaine F Walker; Scott W Woods; Daniel H Mathalon Journal: Int J Methods Psychiatr Res Date: 2020-03-30 Impact factor: 4.035